The DNAJC16 Knockout SK-HEP-1 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population targeting the DNAJC16 gene in the human SK-HEP-1 hepatic adenocarcinoma cell line. This polyclonal format provides a heterogeneous pool of cells carrying targeted disruptions introduced by CRISPR/Cas9-mediated gene editing, enabling loss-of-function studies without the confounding effects of clonal selection. The model serves as a versatile tool for investigating DNAJC16 function in liver cancer biology, with each cell carrying unique indel mutations that collectively ablate gene expression across the population. Researchers can leverage this system to explore co-chaperone biology in a disease-relevant context, benefiting from the broad applicability of polyclonal knockout models.
SK-HEP-1 cells were originally derived from the ascitic fluid of a patient with liver adenocarcinoma and represent a well-characterized hepatocellular carcinoma model. These cells display a mixed phenotype with both endothelial and epithelial features, reflecting the complexity of the tumor microenvironment and making them particularly relevant for studying tumor cell plasticity and stromal interactions. Their robust proliferation and extensive use in oncology research provide a reliable platform for genetic modifications aimed at dissecting molecular mechanisms driving liver cancer. The cell line’s unique characteristics allow investigations that bridge epithelial tumor biology and endothelial-like behaviors, offering insights into hepatocellular carcinoma progression and metastasis.
DNAJC16 encodes a J-domain co-chaperone belonging to the HSP40/DnaJ family, which functions as a critical cofactor for HSP70 molecular chaperones. It participates in the HSP70 chaperone cycle by recruiting HSP70 to specific client proteins, thereby facilitating protein folding, translocation, and degradation under both physiological and stress conditions. DNAJC16 expression is regulated by heat shock factor 1 (HSF1) and sensors of the unfolded protein response (UPR), positioning it at the intersection of cellular stress signaling and proteostasis. Its downstream effects are mediated through HSP70 client proteins, and it interacts with other DnaJ family members and nucleotide exchange factors (NEFs) to modulate chaperone activity. Disruption of DNAJC16 is anticipated to impair protein quality control, particularly affecting the UPR and HSP70-mediated folding pathways, thereby compromising the cell’s ability to manage proteotoxic stress.
In the SK-HEP-1 hepatocellular carcinoma background, loss of DNAJC16 function may exacerbate the intrinsic proteotoxic stress characteristic of rapidly dividing cancer cells. Tumor cells often rely on robust protein quality control systems for survival, making this knockout model valuable for elucidating how co-chaperone dysfunction impacts hepatocellular carcinoma progression. The model can reveal dependencies on DNAJC16 for maintaining proteostasis under conditions such as endoplasmic reticulum stress, potentially sensitizing cells to therapeutic agents that target protein homeostasis. By studying DNAJC16 knockout in this context, researchers can gain insights into the adaptive mechanisms of liver cancer cells and identify vulnerabilities related to chaperone networks that could be exploited for therapeutic intervention.
This polyclonal knockout cell population is suited to a variety of research applications, including the study of co-chaperone function in liver cancer, protein homeostasis, and functional genomics of DnaJ proteins. Representative assays include western blotting and RT-qPCR to confirm target disruption and assess HSP70 pathway activity, co-immunoprecipitation to map altered protein interactions, RNA-seq for transcriptomic profiling, and cell viability assays under ER stress induction using agents like tunicamycin or thapsigargin. HSP70 activity assays can directly evaluate chaperone function changes. The model enables detailed mechanistic studies and drug screening efforts focused on protein quality control in hepatocellular carcinoma. For additional information, please contact Ascent Research.
